Blood thinners in cancer patients with blood clots
Part of Heart & circulation clinical trials.
This study looks at how well blood thinners (anticoagulants) work in people with cancer who have had a blood clot. It aims to compare the benefits and risks of different anticoagulant medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed blood clot — either deep vein thrombosis (DVT), pulmonary embolism (PE), or a clot related to a central line (CVC).
- You must have a current or recently active solid tumor or blood cancer (like leukemia or lymphoma).
- There are no exclusion criteria, so most people who meet the above requirements can join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two blood-thinning medications, edoxaban and apixaban, in people who have both cancer and a blood clot. The goal is to see which one works better and is safer for preventing another clot while treating your cancer.
This study tests whether a blood test and computer program can help doctors decide how long you need to take blood thinners after a cancer-related blood clot. If you've been on a blood thinner for a few months and have certain cancers, this trial may offer a more personalized approach.
This trial tests whether continuing a lower dose of blood thinners can prevent another blood clot in cancer patients who have had a clot in an arm or chest catheter. It may help find a safer way to prevent future clots.
This study looks at whether doctors can predict blood clots in people with certain cancers who are receiving chemotherapy. If you have ovarian, lung, stomach, or pancreatic cancer and are starting chemotherapy, you may be able to join and help improve clot prevention.
This trial is testing a program to help prevent blood clots in people with cancer who are starting a new type of cancer treatment, like chemotherapy or targeted therapy. The goal is to see if better prevention strategies can keep you safe during treatment.
This study looks for “biomarkers,” or blood signs, that may help detect hidden (occult) cancer in people who recently had a blood clot in the leg or a lung clot. It may help doctors catch cancer earlier by improving detection after venous thromboembolism.
Hear when a new Venous Thromboembolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.